Current Report Filing (8-k)
May 09 2023 - 10:56AM
Edgar (US Regulatory)
0001827855
false
0001827855
2023-05-05
2023-05-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 5, 2023
MEDICALE CORP.
(Exact name of registrant
as specified in its charter)
| Nevada |
|
333-250025 |
|
98-1556944 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
9314 Forest Hill Blvd #929
Wellington, FL 33411
(Address of Principal Executive Offices)
(407) 245-7339
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 4.01. Change in Registrant’s Certifying Accountant.
(a) Dismissal of Former Independent Registered
Public Accounting Firm
On May 5, 2023, the Board
of Directors of Medicale Corp. (the “Company”) approved the dismissal of Mac Accounting Group & CPAs, LLP (“Mac
Accounting”) as the Company’s independent registered public accounting firm, effective immediately.
Mac Accounting’s reports
on the Company’s financial statements as of and for the years ended September 30, 2022 and 2021 contained no adverse opinion or
disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except to indicate
that there is substantial doubt as to their ability to continue as a going concern
In connection with the audits
of the Company's consolidated financial statements for the fiscal years ended September 30, 2022 and 2021, and in the subsequent interim
period through May 5, 2023, there were no disagreements with Mac Accounting on any matters of accounting principles or practices, financial
statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of Mac Accounting, would have caused
Mac Accounting to make reference to the matter in their report. There were no reportable events (as that term is described in Item 304(a)(1)(v)
of Regulation S-K) during the two fiscal years ended September 30, 2022 and 2021, or in the subsequent interim period through May 5, 2023.
In accordance with Item 304(a)(3) of Regulation
S-K, on May 8, 2023, the Company provided Mac Accounting with a copy of the foregoing disclosures and requested that Mac Accounting provide
a letter addressed to the SEC stating whether it agrees with such disclosures. A copy of Mac Accounting’s letter dated May 8, 2023
is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) Appointment of New Independent Registered
Public Accounting Firm
On May 5, 2023, the Board
of Directors of the Company approved the appointment of Gries & Associates, LLC (“Gries & Associates”) as the Company’s
new independent registered public accounting firm for the fiscal year ending September 30, 2023. During the Company’s two most recent
fiscal years September 30, 2022 and 2021, and in the subsequent interim period through May 5, 2023, neither the Company nor anyone acting
on its behalf consulted with Gries & Associates with respect to either (i) the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit opinion that might be rendered on the consolidated financial statements
of the Company, and no written report or oral advice was provided by Gries & Associates to the Company that Gries & Associates
concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting
issue, or (ii) any matter that was the subject of either a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable
event (as described in Item 304(a)(1)(v) of Regulation S-K).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Medicale Corp. |
|
| |
|
|
| |
|
|
| Date: May 9, 2023 |
By: |
/s/ J. Chen Zu De |
|
| |
|
Name: Chen Zu De |
|
| |
|
Title: Chief Executive Officer and Chief Financial Officer |
|
Medicale (PK) (USOTC:MCLE)
Historical Stock Chart
From Apr 2024 to May 2024
Medicale (PK) (USOTC:MCLE)
Historical Stock Chart
From May 2023 to May 2024
